Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.63 |
| ▸ | TK2 | O00142 | 3/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.55 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41007 | 1.00 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL18512922 | 1.00 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL14853801 | 1.00 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL41006 | 1.00 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL14929134 | 1.00 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL157586 | 0.88 | PYGM (0.52) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL157193 | 0.88 | PYGM (0.49) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL157587 | 0.88 | PYGM (0.52) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL216337 | 0.88 | PYGM (0.61) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL157194 | 0.88 | PYGM (0.49) | PYGMTK2DNPH1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170044619-A1 | PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | PYGM 1594/4885TK2 151/4885DNPH1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.